<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37107688</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4425</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>17</Day></PubDate></JournalIssue><Title>Genes</Title><ISOAbbreviation>Genes (Basel)</ISOAbbreviation></Journal><ArticleTitle>Young Onset Alzheimer's Disease Associated with <i>C9ORF72</i> Hexanucleotide Expansion: Further Evidence for a Still Unsolved Association.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">930</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/genes14040930</ELocationID><Abstract><AbstractText>Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are recognized as part of a disease continuum (FTD-ALS spectrum), in which the most common genetic cause is chromosome 9 open reading frame 72 (<i>C9ORF72</i>) gene hexanucleotide repeat expansion. The clinical phenotype of patients carrying this expansion varies widely and includes diseases beyond the FTD-ALS spectrum. Although a few cases of patients with <i>C9ORF72</i> expansion and a clinical or biomarker-supported diagnosis of Alzheimer's disease (AD) have been described, they have been considered too sparse to establish a definite association between the <i>C9ORF72</i> expansion and AD pathology. Here, we describe a <i>C9ORF72</i> family with pleomorphic phenotypical expressions: a 54-year-old woman showing cognitive impairment and behavioral disturbances with both neuroimaging and cerebrospinal fluid (CSF) biomarkers consistent with AD pathology, her 49-year-old brother with typical FTD-ALS, and their 63-year-old mother with the behavioral variant of FTD and CSF biomarkers suggestive of AD pathology. The young onset of disease in all three family members and their different phenotypes and biomarker profiles make the simple co-occurrence of different diseases an extremely unlikely explanation. Our report adds to previous findings and may contribute to further expanding the spectrum of diseases associated with <i>C9ORF72</i> expansion.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vinceti</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neurology Unit, Azienda Ospedaliero Universitaria di Modena, 41126 Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallingani</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5057-0181</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Azienda Ospedaliero Universitaria di Modena, 41126 Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zucchi</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neurology Unit, Azienda Ospedaliero Universitaria di Modena, 41126 Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinelli</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-2566-3671</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Azienda Ospedaliero Universitaria di Modena, 41126 Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gianferrari</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-4260-0915</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Azienda Ospedaliero Universitaria di Modena, 41126 Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonini</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-5456-2365</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Azienda Ospedaliero Universitaria di Modena, 41126 Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedin</LastName><ForeName>Roberta</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Neurology Unit, Azienda Ospedaliero Universitaria di Modena, 41126 Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiari</LastName><ForeName>Annalisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurology Unit, Azienda Ospedaliero Universitaria di Modena, 41126 Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zamboni</LastName><ForeName>Giovanna</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neurology Unit, Azienda Ospedaliero Universitaria di Modena, 41126 Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandrioli</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9244-9782</Identifier><AffiliationInfo><Affiliation>Neurology Unit, Azienda Ospedaliero Universitaria di Modena, 41126 Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Genes (Basel)</MedlineTA><NlmUniqueID>101551097</NlmUniqueID><ISSNLinking>2073-4425</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C566288">Frontotemporal Dementia With Motor Neuron Disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">C9ORF72</Keyword><Keyword MajorTopicYN="N">Frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>1</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37107688</ArticleId><ArticleId IdType="pmc">PMC10138077</ArticleId><ArticleId IdType="doi">10.3390/genes14040930</ArticleId><ArticleId IdType="pii">genes14040930</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Majounie E., Renton A.E., Mok K., Dopper E.G.P., Waite A., Rollinson S., Chi&#xf2; A., Restagno G., Nicolaou N., Simon-Sanchez J., et al. Frequency of the C9orf72 Hexanucleotide Repeat Expansion in Patients with Amyotrophic Lateral Sclerosis and Frontotemporal Dementia: A Cross-Sectional Study. Lancet Neurol. 2012;11:323&#x2013;330. doi: 10.1016/S1474-4422(12)70043-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70043-1</ArticleId><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M., Gijselinck I., Van Langenhove T., van der Zee J., Van Broeckhoven C. Current Insights into the C9orf72 Repeat Expansion Diseases of the FTLD/ALS Spectrum. Trends Neurosci. 2013;36:450&#x2013;459. doi: 10.1016/j.tins.2013.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2013.04.010</ArticleId><ArticleId IdType="pubmed">23746459</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J., Mediani L., Alberti S., Carra S. ALS and FTD: Where RNA Metabolism Meets Protein Quality Control. Semin. Cell Dev. Biol. 2020;99:183&#x2013;192. doi: 10.1016/j.semcdb.2019.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcdb.2019.06.003</ArticleId><ArticleId IdType="pubmed">31254610</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C., Ravenscroft T.A., Sanchez-Contreras M., Rademakers R. Genetics of FTLD: Overview and What Else We Can Expect from Genetic Studies. J. Neurochem. 2016;138((Suppl. S1)):32&#x2013;53. doi: 10.1111/jnc.13622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13622</ArticleId><ArticleId IdType="pubmed">27009575</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Mossevelde S., van der Zee J., Cruts M., Van Broeckhoven C. Relationship between C9orf72 Repeat Size and Clinical Phenotype. Curr. Opin. Genet. Dev. 2017;44:117&#x2013;124. doi: 10.1016/j.gde.2017.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gde.2017.02.008</ArticleId><ArticleId IdType="pubmed">28319737</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R., Neumann M., Mackenzie I.R. Advances in Understanding the Molecular Basis of Frontotemporal De-mentia. Nat. Rev. Neurol. 2012;8:423&#x2013;434. doi: 10.1038/nrneurol.2012.117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2012.117</ArticleId><ArticleId IdType="pmc">PMC3629543</ArticleId><ArticleId IdType="pubmed">22732773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensman Moss D.J., Poulter M., Beck J., Hehir J., Polke J.M., Campbell T., Adamson G., Mudanohwo E., McColgan P., Haworth A., et al. C9orf72 Expansions Are the Most Common Genetic Cause of Huntington Disease Phenocopies. Neurology. 2014;82:292&#x2013;299. doi: 10.1212/WNL.0000000000000061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000061</ArticleId><ArticleId IdType="pmc">PMC3929197</ArticleId><ArticleId IdType="pubmed">24363131</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C., Pomper J.K., Biskup S., Pusk&#xe1;s C., Berg D., Synofzik M. Atypical Parkinsonism in C9orf72 Expansions: A Case Report and Systematic Review of 45 Cases from the Literature. J. Neurol. 2016;263:558&#x2013;574. doi: 10.1007/s00415-016-8021-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-016-8021-7</ArticleId><ArticleId IdType="pubmed">26810719</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindquist S.G., Duno M., Batbayli M., Puschmann A., Braendgaard H., Mardosiene S., Svenstrup K., Pinborg L.H., Vestergaard K., Hjermind L.E., et al. Corticobasal and Ataxia Syndromes Widen the Spectrum of C9ORF72 Hexanucleotide Expansion Disease. Clin. Genet. 2013;83:279&#x2013;283. doi: 10.1111/j.1399-0004.2012.01903.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-0004.2012.01903.x</ArticleId><ArticleId IdType="pubmed">22650353</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavallieri F., Mandrioli J., Rosafio F., Contardi S., Fasano A., Menozzi E., Caponnetto C., Chi&#xf2; A., Valzania F. C9ORF72 and Parkinsonism: Weak Link, Innocent Bystander, or Central Player in Neurodegeneration? J. Neurol. Sci. 2017;378:49&#x2013;51. doi: 10.1016/j.jns.2017.04.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2017.04.027</ArticleId><ArticleId IdType="pubmed">28566177</ArticleId></ArticleIdList></Reference><Reference><Citation>Theuns J., Verstraeten A., Sleegers K., Wauters E., Gijselinck I., Smolders S., Crosiers D., Corsmit E., Elinck E., Sharma M., et al. Global Investigation and Meta-Analysis of the C9orf72 (G4C2)n Repeat in Parkinson Disease. Neurology. 2014;83:1906&#x2013;1913. doi: 10.1212/WNL.0000000000001012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001012</ArticleId><ArticleId IdType="pmc">PMC4248456</ArticleId><ArticleId IdType="pubmed">25326098</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuytemans K., Bademci G., Kohli M.M., Beecham G.W., Wang L., Young J.I., Nahab F., Martin E.R., Gilbert J.R., Be-natar M., et al. C9ORF72 Intermediate Repeat Copies Are a Significant Risk Factor for Parkinson Disease. Ann. Hum. Genet. 2013;77:351&#x2013;363. doi: 10.1111/ahg.12033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ahg.12033</ArticleId><ArticleId IdType="pmc">PMC3815478</ArticleId><ArticleId IdType="pubmed">23845100</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E., Abramzon Y., Renton A.E., Perry R., Bassett S.S., Pletnikova O., Troncoso J.C., Hardy J., Singleton A.B., Traynor B.J. Repeat Expansion in C9ORF72 in Alzheimer&#x2019;s Disease. N. Engl. J. Med. 2012;366:283&#x2013;284. doi: 10.1056/NEJMc1113592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1113592</ArticleId><ArticleId IdType="pmc">PMC3513272</ArticleId><ArticleId IdType="pubmed">22216764</ArticleId></ArticleIdList></Reference><Reference><Citation>Wojtas A., Heggeli K.A., Finch N., Baker M., Dejesus-Hernandez M., Younkin S.G., Dickson D.W., Graff-Radford N.R., Rademakers R. C9ORF72 Repeat Expansions and Other FTD Gene Mutations in a Clinical AD Patient Series from Mayo Clinic. Am. J. Neurodegener. Dis. 2012;1:107&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560455</ArticleId><ArticleId IdType="pubmed">23383383</ArticleId></ArticleIdList></Reference><Reference><Citation>Harms M., Benitez B.A., Cairns N., Cooper B., Cooper P., Mayo K., Carrell D., Faber K., Williamson J., Bird T., et al. C9orf72 Hexanucleotide Repeat Expansions in Clinical Alzheimer Disease. JAMA Neurol. 2013;70:736&#x2013;741. doi: 10.1001/2013.jamaneurol.537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/2013.jamaneurol.537</ArticleId><ArticleId IdType="pmc">PMC3681841</ArticleId><ArticleId IdType="pubmed">23588422</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacace R., Van Cauwenberghe C., Bettens K., Gijselinck I., van der Zee J., Engelborghs S., Vandenbulcke M., Van Dongen J., B&#xe4;umer V., Dillen L., et al. C9orf72 G4C2 Repeat Expansions in Alzheimer&#x2019;s Disease and Mild Cognitive Impairment. Neurobiol. Aging. 2013;34:1712.e1&#x2013;1712.e7. doi: 10.1016/j.neurobiolaging.2012.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.12.019</ArticleId><ArticleId IdType="pubmed">23352322</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck J., Poulter M., Hensman D., Rohrer J.D., Mahoney C.J., Adamson G., Campbell T., Uphill J., Borg A., Fratta P., et al. Large C9orf72 Hexanucleotide Repeat Expansions Are Seen in Multiple Neurodegenerative Syndromes and Are More Frequent than Expected in the UK Population. Am. J. Hum. Genet. 2013;92:345&#x2013;353. doi: 10.1016/j.ajhg.2013.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2013.01.011</ArticleId><ArticleId IdType="pmc">PMC3591848</ArticleId><ArticleId IdType="pubmed">23434116</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrone F., Cacace R., Van Mossevelde S., Van den Bossche T., De Deyn P.P., Cras P., Engelborghs S., van der Zee J., Van Broeckhoven C. Genetic Screening in Early-Onset Dementia Patients with Unclear Phenotype: Relevance for Clinical Diagnosis. Neurobiol. Aging. 2018;69:e7&#x2013;e292. doi: 10.1016/j.neurobiolaging.2018.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.04.015</ArticleId><ArticleId IdType="pubmed">29859640</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehrabian S., Thonberg H., Raycheva M., Lilius L., Stoyanova K., Forsell C., Cavallin L., Nesheva D., Westman E., Toncheva D., et al. Phenotypic Variability and Neuropsychological Findings Associated with C9orf72 Repeat Expansions in a Bulgarian Dementia Cohort. PLoS ONE. 2018;13:e0208383. doi: 10.1371/journal.pone.0208383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0208383</ArticleId><ArticleId IdType="pmc">PMC6294384</ArticleId><ArticleId IdType="pubmed">30550541</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasanen P., Myllykangas L., P&#xf6;yh&#xf6;nen M., Kiviharju A., Siitonen M., Hardy J., Bras J., Paetau A., Tienari P.J., Guerreiro R., et al. Genetics of Dementia in a Finnish Cohort. Eur. J. Hum. Genet. 2018;26:827&#x2013;837. doi: 10.1038/s41431-018-0117-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-018-0117-3</ArticleId><ArticleId IdType="pmc">PMC5974394</ArticleId><ArticleId IdType="pubmed">29476165</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos E.M., Dokuru D.R., Van Berlo V., Wojta K., Wang Q., Huang A.Y., Deverasetty S., Qin Y., van Blitterswijk M., Jackson J., et al. Genetic Screening of a Large Series of North American Sporadic and Familial Frontotemporal Dementia Cases. Alzheimer&#x2019;s Dement. 2020;16:118&#x2013;130. doi: 10.1002/alz.12011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12011</ArticleId><ArticleId IdType="pmc">PMC7199807</ArticleId><ArticleId IdType="pubmed">31914217</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;nig T., Wurm R., Parvizi T., Silvaieh S., Hotzy C., Cetin H., Klotz S., Gelpi E., Bancher C., Benke T., et al. C9orf72 Re-peat Length Might Influence Clinical Sub-Phenotypes in Dementia Patients. Neurobiol. Dis. 2022;175:105927. doi: 10.1016/j.nbd.2022.105927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2022.105927</ArticleId><ArticleId IdType="pubmed">36379394</ArticleId></ArticleIdList></Reference><Reference><Citation>Kartanou C., Kontogeorgiou Z., Rentzos M., Potagas C., Aristeidou S., Kapaki E., Paraskevas G.P., Constantinides V.C., Stefanis L., Papageorgiou S.G., et al. Expanding the Spectrum of C9ORF72-Related Neurodegenerative Disorders in the Greek Population. J. Neurol. Sci. 2022;442:120450. doi: 10.1016/j.jns.2022.120450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2022.120450</ArticleId><ArticleId IdType="pubmed">36252286</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray M.E., DeJesus-Hernandez M., Rutherford N.J., Baker M., Duara R., Graff-Radford N.R., Wszolek Z.K., Fer-man T., Josephs K.A., Boylan K.B., et al. Clinical and Neuropathologic Heterogeneity of C9FTD/ALS Associated with Hexanu-cleotide Repeat Expansion in C9ORF72. Acta Neuropathol. 2011;122:673&#x2013;690. doi: 10.1007/s00401-011-0907-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0907-y</ArticleId><ArticleId IdType="pmc">PMC3277860</ArticleId><ArticleId IdType="pubmed">22083254</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohli M.A., John-Williams K., Rajbhandary R., Naj A., Whitehead P., Hamilton K., Carney R.M., Wright C., Crocco E., Gwirtzman H.E., et al. Repeat Expansions in the C9ORF72 Gene Contribute to Alzheimer&#x2019;s Disease in Caucasians. Neurobiol. Aging. 2013;34:1519.e5&#x2013;1519.e12. doi: 10.1016/j.neurobiolaging.2012.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.10.003</ArticleId><ArticleId IdType="pmc">PMC3586789</ArticleId><ArticleId IdType="pubmed">23107433</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J., Zucchi E., Martinelli I., Van der Most L., Gianferrari G., Moglia C., Manera U., Solero L., Vasta R., Ca-nosa A., et al. Factors Predicting Disease Progression in C9ORF72 ALS Patients. J. Neurol. 2023;270:877&#x2013;890. doi: 10.1007/s00415-022-11426-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11426-y</ArticleId><ArticleId IdType="pubmed">36280624</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermunt L., Otte M., Verberk I.M.W., Killestein J., Lemstra A.W., van der Flier W.M., Pijnenburg Y.A.L., Vijverberg E.G.B., Bouwman F.H., Gravesteijn G., et al. Age- and Disease-Specific Reference Values for Neurofilament Light Presented in an Online Interactive Support Interface. Ann. Clin. Transl. Neurol. 2022;9:1832&#x2013;1837. doi: 10.1002/acn3.51676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51676</ArticleId><ArticleId IdType="pmc">PMC9639622</ArticleId><ArticleId IdType="pubmed">36196979</ArticleId></ArticleIdList></Reference><Reference><Citation>Filikci Z., Gustafsson M.A.K., Henriksen O.M., Marner L., H&#xf8;gh P. C9ORF72 Hexanucleotide Repeat Expansion with Alzheimer&#x2019;s Disease-like Clinical Phenotype: A Case Report with Results from Neuropsychology, CSF, FDG-PET, and PiB-PET. Clin. Case Rep. 2020;8:3416&#x2013;3420. doi: 10.1002/ccr3.3417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccr3.3417</ArticleId><ArticleId IdType="pmc">PMC7752426</ArticleId><ArticleId IdType="pubmed">33363944</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallucci M., Dell&#x2019;Acqua C., Bergamelli C., Fenoglio C., Serpente M., Galimberti D., Fiore V., Medea S., Gregianin M., Di Battista M.E. A Case with Early Onset Alzheimer&#x2019;s Disease, Frontotemporal Hypometabolism, ApoE Genotype &#x3b5;4/&#x3b5;4 and C9ORF72 Intermediate Expansion: A Treviso Dementia (TREDEM) Registry Case Report. J. Alzheimer&#x2019;s Dis. 2019;67:985&#x2013;993. doi: 10.3233/JAD-180715.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-180715</ArticleId><ArticleId IdType="pubmed">30714955</ArticleId></ArticleIdList></Reference><Reference><Citation>Sha S.J., Khazenzon A.M., Ghosh P.M., Rankin K.P., Pribadi M., Coppola G., Geschwind D.H., Rabinovici G.D., Mil-ler B.L., Lee S.E. Early-Onset Alzheimer&#x2019;s Disease versus Frontotemporal Dementia: Resolution with Genetic Diagnoses? Neurocase. 2016;22:161&#x2013;167. doi: 10.1080/13554794.2015.1080283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13554794.2015.1080283</ArticleId><ArticleId IdType="pmc">PMC4733403</ArticleId><ArticleId IdType="pubmed">26304661</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallon D., Rovelet-Lecrux A., Deramecourt V., Pariente J., Auriacombe S., Le Ber I., Schraen S., Pasquier F., Campion D., Hannequin D. Definite Behavioral Variant of Frontotemporal Dementia with C9ORF72 Expansions despite Positive Alzheimer&#x2019;s Disease Cerebrospinal Fluid Biomarkers. J. Alzheimer&#x2019;s Dis. 2012;32:19&#x2013;22. doi: 10.3233/JAD-2012-120877.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-120877</ArticleId><ArticleId IdType="pubmed">22766732</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xe4;m&#xe4;l&#xe4;inen A., Herukka S.-K., Hartikainen P., Helisalmi S., Moilanen V., Knuuttila A., Jansson L., Tienari P.J., Remes A.M. Cerebrospinal Fluid Biomarkers for Alzheimer&#x2019;s Disease in Patients with Frontotemporal Lobar Degeneration and Amyo-trophic Lateral Sclerosis with the C9ORF72 Repeat Expansion. Dement. Geriatr. Cogn. Disord. 2015;39:287&#x2013;293. doi: 10.1159/000371704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000371704</ArticleId><ArticleId IdType="pubmed">25791939</ArticleId></ArticleIdList></Reference><Reference><Citation>Junttila A., Kuvaja M., Hartikainen P., Siloaho M., Helisalmi S., Moilanen V., Kiviharju A., Jansson L., Tienari P.J., Remes A.M., et al. Cerebrospinal Fluid TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis Pa-tients with and without the C9ORF72 Hexanucleotide Expansion. Dement. Geriatr. Cogn. Disord. Extra. 2016;6:142&#x2013;149. doi: 10.1159/000444788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000444788</ArticleId><ArticleId IdType="pmc">PMC4868946</ArticleId><ArticleId IdType="pubmed">27195002</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieniek K.F., Murray M.E., Rutherford N.J., Castanedes-Casey M., DeJesus-Hernandez M., Liesinger A.M., Baker M.C., Boylan K.B., Rademakers R., Dickson D.W. Tau Pathology in Frontotemporal Lobar Degeneration with C9ORF72 Hexanucleo-tide Repeat Expansion. Acta Neuropathol. 2013;125:289&#x2013;302. doi: 10.1007/s00401-012-1048-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1048-7</ArticleId><ArticleId IdType="pmc">PMC3551994</ArticleId><ArticleId IdType="pubmed">23053135</ArticleId></ArticleIdList></Reference><Reference><Citation>King A., Al-Sarraj S., Troakes C., Smith B.N., Maekawa S., Iovino M., Spillantini M.G., Shaw C.E. Mixed Tau, TDP-43 and P62 Pathology in FTLD Associated with a C9ORF72 Repeat Expansion and p.Ala239Thr MAPT (Tau) Variant. Acta Neuropathol. 2013;125:303&#x2013;310. doi: 10.1007/s00401-012-1050-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1050-0</ArticleId><ArticleId IdType="pubmed">23053136</ArticleId></ArticleIdList></Reference><Reference><Citation>Savva G.M., Wharton S.B., Ince P.G., Forster G., Matthews F.E., Brayne C., Medical Research Council Cognitive Func-tion and Ageing Study Age, Neuropathology, and Dementia. N. Engl. J. Med. 2009;360:2302&#x2013;2309. doi: 10.1056/NEJMoa0806142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0806142</ArticleId><ArticleId IdType="pubmed">19474427</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiari A., Vinceti G., Adani G., Tondelli M., Galli C., Fiondella L., Costa M., Molinari M.A., Filippini T., Zamboni G., et al. Epidemiology of Early Onset Dementia and Its Clinical Presentations in the Province of Modena, Italy. Alzheimer&#x2019;s Dement. 2021;17:81&#x2013;88. doi: 10.1002/alz.12177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/alz.12177</ArticleId><ArticleId IdType="pubmed">32914938</ArticleId></ArticleIdList></Reference><Reference><Citation>Saint-Aubert L., Sagot C., Wallon D., Hannequin D., Payoux P., Nemmi F., Bezy C., Chauveau N., Campion D., Puel M., et al. A Case of Logopenic Primary Progressive Aphasia with C9ORF72 Expansion and Cortical Florbetapir Binding. J. Alzheimer&#x2019;s Dis. 2014;42:413&#x2013;420. doi: 10.3233/JAD-140222.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-140222</ArticleId><ArticleId IdType="pubmed">24898647</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh J.-I., Tabunoki H., Ishida T., Saito Y., Arima K. Dystrophic Neurites Express C9orf72 in Alzheimer&#x2019;s Disease Brains. Alzheimer&#x2019;s Res. Ther. 2012;4:33. doi: 10.1186/alzrt136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt136</ArticleId><ArticleId IdType="pmc">PMC3506947</ArticleId><ArticleId IdType="pubmed">22898310</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Zee J., Gijselinck I., Dillen L., Van Langenhove T., Theuns J., Engelborghs S., Philtjens S., Vandenbulcke M., Sleegers K., Sieben A., et al. A Pan-European Study of the C9orf72 Repeat Associated with FTLD: Geographic Prevalence, Ge-nomic Instability, and Intermediate Repeats. Hum. Mutat. 2013;34:363&#x2013;373. doi: 10.1002/humu.22244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22244</ArticleId><ArticleId IdType="pmc">PMC3638346</ArticleId><ArticleId IdType="pubmed">23111906</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I., Van Mossevelde S., van der Zee J., Sieben A., Engelborghs S., De Bleecker J., Ivanoiu A., Deryck O., Edbauer D., Zhang M., et al. The C9orf72 Repeat Size Correlates with Onset Age of Disease, DNA Methylation and Transcriptional Down-regulation of the Promoter. Mol. Psychiatry. 2016;21:1112&#x2013;1124. doi: 10.1038/mp.2015.159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.159</ArticleId><ArticleId IdType="pmc">PMC4960451</ArticleId><ArticleId IdType="pubmed">26481318</ArticleId></ArticleIdList></Reference><Reference><Citation>Serpente M., Fenoglio C., Arighi A., Fumagalli G.G., Arcaro M., Sorrentino F., Visconte C., Scarpini E., Galimberti D. Analysis of C9orf72 Intermediate Alleles in a Retrospective Cohort of Neurological Patients: Risk Factors for Alzheimer&#x2019;s Disease? J. Alzheimer&#x2019;s Dis. 2021;81:1445&#x2013;1451. doi: 10.3233/JAD-210249.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-210249</ArticleId><ArticleId IdType="pubmed">33935096</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng A.S.L., Tan E.-K. Intermediate C9orf72 Alleles in Neurological Disorders: Does Size Really Matter? J. Med Genet. 2017;54:591&#x2013;597. doi: 10.1136/jmedgenet-2017-104752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2017-104752</ArticleId><ArticleId IdType="pmc">PMC5574395</ArticleId><ArticleId IdType="pubmed">28689190</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu L., Sun Q., Zhang Y., Xu Q., Guo J., Yan X., Tang B. The Association between C9orf72 Repeats and Risk of Alz-heimer&#x2019;s Disease and Amyotrophic Lateral Sclerosis: A Meta-Analysis. Park. Dis. 2016;2016:5731734. doi: 10.1155/2016/5731734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/5731734</ArticleId><ArticleId IdType="pmc">PMC4916312</ArticleId><ArticleId IdType="pubmed">27375918</ArticleId></ArticleIdList></Reference><Reference><Citation>Lall D., Lorenzini I., Mota T.A., Bell S., Mahan T.E., Ulrich J.D., Davtyan H., Rexach J.E., Muhammad A.K.M.G., Shelest O., et al. C9orf72 Deficiency Promotes Microglial-Mediated Synaptic Loss in Aging and Amyloid Accumulation. Neuron. 2021;109:2275&#x2013;2291.e8. doi: 10.1016/j.neuron.2021.05.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.05.020</ArticleId><ArticleId IdType="pmc">PMC8298293</ArticleId><ArticleId IdType="pubmed">34133945</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Jiang Y., Huang Z. Loss of C9orf72 in Microglia Drives Neuronal Injury by Enhancing Synaptic Pruning in Aged and Alzheimer&#x2019;s Disease Mice. Neurosci. Bull. 2022;38:327&#x2013;330. doi: 10.1007/s12264-021-00796-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-021-00796-4</ArticleId><ArticleId IdType="pmc">PMC8975903</ArticleId><ArticleId IdType="pubmed">34783984</ArticleId></ArticleIdList></Reference><Reference><Citation>Leskel&#xe4; S., Takalo M., Marttinen M., Huber N., Paananen J., Mitra V., Rauramaa T., M&#xe4;kinen P., Leinonen V., Soininen H., et al. Interrelationship between the Levels of C9orf72 and Amyloid-&#x3b2; Protein Precursor and Amyloid-&#x3b2; in Human Cells and Brain Samples. J. Alzheimer&#x2019;s Dis. 2018;62:269&#x2013;278. doi: 10.3233/JAD-170362.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-170362</ArticleId><ArticleId IdType="pubmed">29439323</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>